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Progressive familial intrahepatic cholestasis type 3 (PFIC3) is a rare monogenic disease
caused by mutations in the ABCB4 gene, resulting in a reduction in biliary phosphati-
dylcholine. Reduced biliary phosphatidylcholine cannot counteract the detergent effects of
bile salts, leading to cholestasis, cholangitis, cirrhosis and ultimately liver failure. Here, we
report results from treating two- or five-week-old Abcb4−/− mice with an AAV vector
expressing human ABCB4, resulting in significant decreases of PFIC3 disease biomarkers. All
male mice achieved a sustained therapeutic effect up through 12 weeks, but the effect was
achieved in only 50% of females. However, two-week-old females receiving a second
inoculation three weeks later maintained the therapeutic effect. Upon sacrifice, markers of
PFIC3 disease such as, hepatosplenomegaly, biliary phosphatidylcholine and liver histology
were significantly improved. Thus, AAV-mediated gene therapy successfully prevented
PFIC3 symptoms in a clinically relevant mouse model, representing a step forward in
improving potential therapy options for PFIC3 patients.
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Progressive familial intrahepatic cholestasis (PFIC) describesa genetically heterogeneous group of inherited diseases, ofwhich several types arise from abnormalities in a few
transporters involved in bile production and regulation, which are
mostly expressed in the canalicular membrane of hepatocytes1. In
the case of PFIC type 3 (PFIC3, or MDR3 deficiency associated
with PFIC), mutations affect the ABCB4 gene, which encodes for
multidrug resistance protein 3 (MDR3), a floppase involved in the
translocation of phosphatidylcholine (PC) from the hepatocyte
membrane to the bile. PC is an important component of bile,
which is necessary to form mixed micelles with bile salts and
cholesterol2. In the absence of PC, the bile acquires detergent
properties and becomes very toxic to the membrane of hepato-
cytes and cholangiocytes, resulting in biliary canaliculi and epi-
thelium injury, leading to cholestasis, cirrhosis, and ultimately
liver failure3. In addition, the low level of phospholipids in bile
often leads to crystallization of cholesterol, resulting in bile duct
obstruction.
PFIC3 is a rare autosomal recessive disease that affects
approximately 1 in 100,000 people worldwide4. More than 30
different mutations in ABCB4 have been identified in PFIC3
patients, with one-third of mutations resulting in expression of a
truncated MDR3 protein. Since mutations can alter the func-
tionality of MDR3 in many different ways, the phenotype of
PFIC3 patients shows a high degree of variability. Signs of cho-
lestasis usually appear within the first year of life, although
sometimes they are not detected until late childhood or even early
adulthood4. In general, patients have high serum levels of bile
salts and transaminases and moderate pruritus. The standard of
care for PFIC3 patients is based on administration of urso-
deoxycholic acid (UDCA), a hydrophilic bile salt that can replace
more toxic hydrophobic bile salts in the liver5. However, only
~50% of patients benefit from UDCA therapy, and a liver
transplant is the only curative treatment. Given the risks and high
cost inherent with liver transplantation, new therapy options for
PFIC3 patients are highly desirable. For example, gene therapy
approaches based on gene correction or supplementation could
provide a definitive cure for PFIC3 patients. Gene therapy is
increasingly demonstrating its value as an innovative and safe
therapeutic approach. Indeed, gene therapy based on the use of
adeno-associated viral vectors (AAVs) has recently shown to
provide safe long-term correction for several genetic diseases like
haemophilia B6,7 and Leber’s congenital amaurosis8.
A mouse model for PFIC3 in which the Abcb4 gene was dis-
rupted by elimination of its two first exons has been described9.
These mice completely lack expression of MDR2 (the mouse
ortholog for human MDR3), and are unable to secrete PC to the
bile. This results in symptoms that reproduce most of the bio-
markers and pathological signs of human PFIC3, including
hepatosplenomegaly and liver fibrosis, although the severity and
progression of the disease varies depending on the mouse
strain10.
In the present study, we have developed a therapeutic strategy
for PFIC3 based on the administration of an AAV8 vector
designed for liver-specific human MDR3 expression in a strain of
Abcb4−/− mice that spontaneously progress to severe biliary
fibrosis11. This therapy was able to increase biliary PC levels,
resulting in normalization of all serum biomarkers, complete
prevention of liver fibrosis and long-term correction of the dis-
ease in treated mice.
Results
Selection of the MDR3 variant. Since three potential isoforms
have been identified for human MDR3 (A, B, and C)12, we tested
first the expression of each isoform in vitro. Isoform B differs
from isoform A due to a seven-amino-acid insertion near the
nucleotide binding domain 2, while isoform C has a 47-amino-
acid deletion that includes transmembrane domain 11 (Fig. 1a).
We generated AAV expression plasmids containing either the
wildtype (wt) or a codon-optimized (co) version of human
MDR3-A, -B, or -C cDNAs under the transcriptional control of
the liver specific alpha-1 antitrypsin (A1AT) promoter (Fig. 1a).
These plasmids were transiently transfected into the human
hepatic cell line HuH-7 in order to analyse and compare
expression and their capacity to transfer PC from the cell cyto-
plasm to the outer space of the cell (floppase activity) of the six
variants. Utilizing immunofluorescence and confocal microscopy,
cells that stained positive for MDR3 expression showed that only
isoform A (wt and co) localized to the cell membrane (Fig. 1b).
Meanwhile, isoforms B and C were expressed only in the cyto-
plasm, suggesting that these two variants are most likely non-
functional at transporting PC across the cell membrane. When
supernatant PC concentration from transfected cells was quan-
tified, differences in floppase activity were detected, revealing
MDR3 isoform A to be on average fourfold and 1.6-fold more
active than isoforms B and C, respectively (Fig. 1c). There were
no differences observed between the wt and co versions for any of
the three isoforms.
Liver expression via hydrodynamic injection of Abcb4−/− mice.
To test for MDR3 expression in vivo, plasmids with the MDR3-
Aco and -Awt variants, were tested in 7-week-old male Abcb4−/−
mice via hydrodynamic injection. The animals were sacrificed
24 h later and MDR3 expression was analysed in liver sections by
immunohistochemistry (IHC). The two mice inoculated with
pAAV-MDR3-Aco showed clear MDR3 expression. In particular,
one mouse showed MDR3 expression in discrete pockets
throughout the liver tissue (Fig. 1d), with MDR3 clearly located
on the canalicular membrane of hepatocytes. In contrast, pAAV-
MDR3-Awt injection resulted in only one animal showing MDR3
expression that could be detected around a single cell from the
entire sample (Fig. 1d). These results suggest that the MDR3-Aco
sequence can be expressed in vivo much more efficiently than
MDR3-Awt.
AAV-MDR3-induced normalization of PFIC3 hepatic bio-
markers. The Abcb4−/− FVB mouse model has shown to reliably
replicate several PFIC3-associated markers, such as elevated
serum liver transaminases, alkaline phosphatase (ALP), bile salts,
and bilirubin; increased liver and spleen size; decreased con-
centration of PC in the bile; and severe morphological abnorm-
alities in the liver, such as fibrosis, collagen deposits, and cell
infiltrates9. The onset of symptoms in these mice appears very
early, at least before 4 weeks of age11.
We first tested the ability of AAV8 vectors harbouring the
codon-optimized MDR3 isoform A cDNA (AAV-MDR3-Aco) to
establish transgene expression in the livers of Abcb4−/− mice.
Two-week-old mice treated via intravenous (IV) injection with
AAV-MDR3-Aco at a dose of 1 × 1014 viral genomes (VG)/kg
showed robust hepatic MDR3 expression at 1 week after
treatment. IHC staining of MDR3 showed diffuse expression
throughout the liver, which was clearly localized to the biliary
canaliculi (Fig. 2a, upper images) and constituted on average 62 ±
13% the level of MDR2 staining observed in Abcb4+/+ (WT)
animals. Twelve weeks after treatment, expression was still
detected in the biliary canaliculi (Fig. 2a, lower images). However,
expression levels had dropped to 31 ± 9.7% of WT mice in males
and 8.5 ± 0.5% in females (Supplementary Fig. 1).
To test for a therapeutic effect of the AAV vector, we first
treated 2-week-old male and female Abcb4−/− mice via IV
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injection with AAV-MDR3-Aco at doses of 3 × 1013 VG/kg (low)
or 1 × 1014 VG/kg (high) and monitored PFIC3 biomarkers in
serum during the following 12 weeks. Male mice treated at the
high dose achieved a sustained therapeutic effect up through
12 weeks, as ALP, alanine transaminase (ALT), aspartate
transaminase (AST) and bile salt levels were all significantly
reduced to levels similar to those observed in WT mice, used as
controls. In contrast, neither saline-treated mice nor mice treated
at the low AAV dose showed a significant reduction in these
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therapeutic effect was also observed, which lasted 6 weeks in
100% of the animals. However, beginning at 8 weeks after
treatment, half of the treated females experienced a waning of the
therapeutic effect demonstrated with the rising of serum hepatic
biomarker levels (Fig. 3b). The other half of the females
maintained low biomarker levels up through 12 weeks.
In order to improve the efficacy of this therapy, we performed a
second study in which Abcb4−/− mice were treated at 2 weeks of
age with the AAV-MDR3-Aco high dose and received a second
high dose 3 weeks later (at 5 weeks of age). In this case, Abcb4−/−
males again showed values for serum hepatic biomarkers similar
to WT mice (Supplementary Fig. 2), and Abcb4−/− females
treated twice also showed a sustained therapeutic effect through
the entire 12-week follow-up (Fig. 3c).
Increase of bile PC and prevention of liver pathology. We
hypothesized that the improvement in serum PFIC3 biomarkers
in Abcb4−/− mice treated with AAV-MDR3-Aco was most likely
due to the restoration of PC secretion into bile, mediated by
MDR3 expression in hepatocytes and localization to the cell
membrane of the biliary canaliculi. To evaluate whether this was
the case, bile from treated mice was harvested from gallbladders
upon sacrifice and PC concentration was measured. Abcb4−/−
mice treated with AAV-MDR3-Aco at the high dose showed
increased PC levels in the bile compared to saline-treated or low-
dose-treated animals. Moreover, PC in the bile of animals treated
with the high dose twice (2×) had on average two times higher PC
levels than those treated only one time (1×) (Fig. 4a). However,
the low vector dose did not have an effect on PC levels.
We also observed improvements in other PFIC3 symptoms.
Liver and spleen sizes were decreased in the high-dose-treated
animals (both 1× and 2×), as ratios of liver-to-body weight
reached near WT values in the 2× females and in both 1× and 2×
males (Fig. 4b and Supplementary Fig. 3). In addition to the
much increased size and stiffness of the liver in the saline-treated
Abcb4−/− mice, histological analysis revealed an advanced degree
of liver damage, including fibrosis and cell infiltrates. As with the
other disease markers, the degree of collagen staining was reduced
significantly to near total elimination in high-dose AAV-treated
Abcb4−/− mice in males (1× and 2×) and 2× females, indicating
near complete loss of fibrosis (Fig. 4c, d). In 1× females, 50% of
Fig. 1 AAV-MDR3 vectors and analysis of plasmid expression. a Diagrams of AAV vectors expressing MDR3 isoforms A–C downstream of the alpha-1
anti-trypsin promoter (A1AT Pr.). Insertion (Inser.) and deletion (Δ) present in isoforms B and C, respectively, are indicated. ITR, AAV inverted terminal
repeats; pA, synthetic polyadenylation signal. bMDR3 expression in vitro. HuH-7 cells were transfected with AAV plasmids containing the indicated MDR3
isoform and analysed at 48 h by confocal immunofluorescence with an antibody specific against MDR3. For MDR3-Aco and MDR3-Awt, images
correspond to representative serial planes of MDR3-positive cells showing clear membrane-localized expression. For isoforms MDR3-B and C, images
showed a combination of all planes since no membrane staining was observed in any plane. Nuclei were stained with DAPI. Scale bar= 10 μm. c MDR3
activity in vitro. PC concentration in the supernatant of cells transfected with AAV plasmids was quantified by fluorometric assay. Cells transfected with a
GFP-expressing plasmid served as negative control (mock). Equivalent transfection efficiencies were verified via qPCR with primers specific for A1AT
promoter. Labels above individual bars indicate significance relative to MDR3-Aco (one-way ANOVA/Tukey’s multiple comparisons test): ns, not
significant, ***, p < 0.001; ****, p < 0.0001. Data are presented as mean ± standard deviation (SD). F values and degrees of freedom (numerator,
denominator): F(6,7)= 151.1. Source data are provided as a Source Data file. dMDR3 expression in vivo. Abcb4−/− mice (KO) were HDI injected with AAV
plasmids harbouring the indicated MDR3-A gene variant, and MDR3 expression was analysed by IHC with an anti-MDR3-specific antibody 24 h later.
Abcb4+/+ (WT) and non-treated KO mice were used as positive and negative controls, respectively. Representative pictures from one mouse in each
group are shown. Scale bar= 100 μm.
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Fig. 2 Analysis of AAV-MDR3-Aco expression in Abcb4−/− mice. Two-week-old Abcb4−/− mice (KO) mice received one (a) or two (c) doses of
1 × 1014 VG/kg of AAV-MDR3-Aco, and MDR3 expression was analysed at the indicated times after the first dose (pt) by IHC with an anti-MDR3-specific
antibody. In c, the second dose was given when mice were 5 weeks old. A female WT mouse is shown as positive control for MDR2 staining (b).
Representative pictures from one mouse in each group are shown. Scale bar= 100 μm.
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animals showed a significant reduction of fibrosis, while in the
rest, the degree of fibrosis was similar to the saline-treated mice
(in Fig. 4d, a representative responder and non-responder female
are each shown). The loss of fibrosis was the clearest evidence of
the therapeutic effect of the treatment.
Although this strain of Abcb4−/− mice has been reported to
develop HCC, it takes 16 months for all mice to develop
tumours13. Since our studies were not sufficiently long to evaluate
this parameter, we analysed several markers of preneoplasia in
our study population, which were sacrificed between 3.5 and
a
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Fig. 3 Serum biomarker levels for AAV-MDR3-Aco-treated Abcb4−/− mice through 12 weeks. The therapeutic effect of AAV treatment is shown in
males (a) and females (b & c) that were treated with AAV-MDR3-Aco at 3 × 1013 VG/kg one time (1×, pink, open triangles; n= 3M (males)/1 F
(females)), at 1 × 1014 VG/kg one time (1×, red, filled circles; n= 7M/6 F), or at 1 × 1014 VG/kg two times (2×, green, filled diamonds; n= 5 F) using as
controls saline-treated (blue, open squares; n= 4M/8 F) and untreated Abcb4+/+ (WT) mice (black, open circles; n= 3M/3 F). Data are presented as
mean+ SD. ALP alkaline phosphatase, ALT alanine transaminase, AST aspartate transaminase, BS bile salts. Source data are provided as a Source Data file.
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Fig. 4 Biliary PC and evidence of cholestasis for Abcb4−/− mice treated with AAV-MDR3-Aco. At the time of sacrifice, PC concentration in bile (a) and
liver weight as a percent of body weight (b) were measured for Abcb4−/− mice treated with AAV-MDR3-Aco at 3 × 1013 VG/kg 1× (pink bars or black
squares; n= 3M/1 F), at 1 × 1014 VG/kg 1× (green bars or green triangles; n= 7M/5 F), or at 1 × 1014 VG/kg 2× (blue bars or blue inverted triangles; n= 3
M/4 F), as well as saline-treated controls (white bars or open circles; n= 4M/8 F) and untreated WT mice (grey bars or grey circles; n= 3M/3 F). Liver
sections were stained with picrosirius red to indicate fibrosis (d) and the amount of tissue with red staining was quantified (c). Representative pictures
from one mouse in each group are shown, except for females treated 1× at 1 × 1014 VG/kg, for which one animal each from both responder (left image) and
non-responder (right image) groups is shown. Scale bar= 500 μm. Statistics (one-way ANOVA/Tukey’s multiple comparisons test): *, p < 0.05; **, p <
0.01; ***, p < 0.001; data are presented as mean ± SD; F values and degrees of freedom (numerator, denominator): a males: F(3,12)= 14.52, females: F
(3,15)= 4.58; b males: F(3,13)= 8.548, females: F(3,14)= 4.501; c males: F(3,13)= 23.13, females: F(3,14)= 11.58. Source data are provided as a Source
Data file.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13614-3
6 NATURE COMMUNICATIONS |         (2019) 10:5694 | https://doi.org/10.1038/s41467-019-13614-3 | www.nature.com/naturecommunications
4.5 months of age. We tested expression levels of glycine N-
methyltransferase (GNMT) and alpha fetoprotein (AFP) genes,
which are downregulated and upregulated, respectively, in both
human HCC and Abcb4−/− mouse liver tumours14–16. In
addition, we also quantified the phosphorylated histone H2AX
(γH2AX) by IHC, an indicator of DNA double-strand breaks that
has been reported to be a good preneoplastic marker of HCC in
Abcb4−/− mice17. Our results showed greater evidence of
preneoplasia in saline-treated Abcb4−/− males than in saline-
treated Abcb4−/− females compared to WT of the same age. In
the males that responded to our AAV treatment (achieving bile
PC concentrations above 3900 μM, see next section and
Discussion), there was a significant improvement compared to
either saline-treated or non-responder males for γH2AX and a
trend towards improvement for GNMT and AFP (Supplementary
Figs. 4, 5). For females, significant improvements were observed
in AFP and γH2AX levels compared to either saline-treated or
non-responder females. However, there was no significant
difference between saline-treated Abcb4−/− and WT females for
any of the markers, despite trends in all three markers. These
results point to a likely reduction in tumour formation in mice
that responded to our therapy.
Transgene expression threshold needed for therapeutic effect.
DNA and RNA were separately extracted from liver tissue of the
study animals upon sacrifice in order to quantify AAV-MDR3-
Aco transduction efficiency and transgene expression. Vector
transduction, as determined by AAV genome copies, was slightly
better in males than females, and was 2- to 2.5-fold higher in the
2× mice compared to the 1× mice for both males and females
(Fig. 5a). The level of MDR3 mRNA closely reflected the trans-
duction efficiency (Fig. 5b). Of note, in the low-dose-treated mice,
the relative levels of genomes and MDR3 mRNA were approxi-
mately 50- to 100-fold lower than in the 1× high-dose-treated
mice, which could explain the lack of therapeutic effect observed
in the low-dose-treated mice. There appears to be an inflection
point in the dose response curve, below which transduction and/
or expression are greatly reduced or lost over time, and above
which a therapeutic effect is possible. In order to determine the
inflection point with greater accuracy, we treated 2-week-old mice
with additional intermediate doses and analysed vector genomes
and MDR3 mRNA at time of sacrifice. This additional study
showed that the inflection point is between 7 × 1013 and 1 × 1014
VG/kg (Supplementary Fig. 6).
IHC staining of liver sections for MDR3 protein confirmed
that, as seen for transduction efficiency, MDR3 expression was
higher in males than females. In addition, the 2× group showed
about twice the amount of protein expression compared to the 1×
group (Figs. 2 and 5c). Again, the low-dose-treated mice showed a
markedly lower MDR3 expression, suggesting that loss of
transgene expression might be more substantial in these animals.
In order to determine whether the amount of MDR3 expression
dictates the outcome of treatment, we analysed the correlation of
MDR3 staining as measured by IHC and the severity of disease
markers, including bile PC concentration, liver size, and fibrosis.
For all markers of PFIC3, there was a clear correlation between
the amount of MDR3 expression and reduction of disease marker
severity (Supplementary Figs. 7–9). This analysis suggests that a
threshold of around 2–3% of WT MDR3 expression would be














































































































Fig. 5 AAV transduction and transgene expression for Abcb4−/− mice
treated with AAV-MDR3-Aco. The levels of AAV genomes (a), MDR3
mRNA transcripts (b), and MDR3 protein expression (c) were quantified
from liver tissue harvested from Abcb4−/− mice treated with AAV-MDR3-
Aco at 3 × 1013 VG/kg 1× (black squares), at 1 × 1014 VG/kg 1× (green
triangles), or at 1 × 1014 VG/kg 2× (blue inverted triangles), as well as
saline-treated controls (open circles). AAV genomes and MDR3 transcripts
were quantified via qPCR and RT-qPCR, respectively, and protein
expression was quantified as the percent area of tissue that stained positive
for MDR3 expression and normalized to levels in WT mice. Animals were
sacrificed between 12 and 16 weeks after treatment. Statistics (one-way
ANOVA/Tukey’s multiple comparisons test): *, p < 0.05; **, p < 0.01; ***,
p < 0.001; data are presented as mean ± SD; F values and degrees of
freedom (numerator, denominator): a males: F(3,13)= 6.057, females: F
(3,14)= 12.74; b males: F(3,13)= 7.59, females: F(3,13)= 4.135; c males: F
(3,13)= 2.073, females: F(3,14)= 5.696. Source data are provided as a
Source Data file.
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levels higher than this value demonstrated clear improvement in
bile PC, liver size, and fibrosis severity.
AAV-MDR3 is effective in 5-week-old Abcb4–/– mice. We were
interested in determining if our vector could induce a therapeutic
effect in older mice, which already present liver inflammation and
fibrosis (Supplementary Fig. 10), to see if an established PFIC3
disease phenotype is unconducive to AAV vector transduction.
Therefore, we treated 5-week-old mice one time with 1 × 1014
VG/kg of AAV-MDR3-Aco. Interestingly, treated mice achieved a
clear therapeutic effect, as ALP, ALT, AST, and bile salt levels
were all significantly reduced to WT levels, with the effect in
males and half of the females lasting up through 12 weeks, while
the effect waned in the other half of females starting about
4–5 weeks after treatment (Fig. 6). Improvements in biological
parameters at sacrifice (hepatosplenomegaly, bile PC concentra-
tion, and fibrosis) were similar as in mice treated at 2 weeks of age
(Fig. 7 and Supplementary Fig. 10). This supports the possibility
of using our AAV vector in mice that already display a disease
phenotype and that liver fibrosis might not constitute an exclu-
sion criterion for potential candidates for therapy.
Discussion
The possibility of addressing PFIC3 with gene therapy holds a
great deal of promise, as it has several favourable aspects that
make it highly suitable for developing this type of treatment. For
instance, PFIC3 is a monogenic disease with the causative gene
expressed exclusively in the liver, and its pathology includes very
well-defined biomarkers18. To study the feasibility of PFIC3 gene
therapy, we used a gene supplementation strategy based on an
AAV8 vector expressing human MDR3 to transduce the liver of
Abcb4−/− mice. The existence of three isoforms of MDR312
required a preliminary selection of the most suitable isoform to
restore MDR3 expression and activity at the liver cell plasma
membrane. This was performed by in vitro analysis, which clearly
showed that isoform A was the only one of the three isoforms with
membrane localization and thus with the potential for function-
ality in transporting PC into the bile. In vitro enzymatic activity
analysis also pointed to the superiority of isoform A over isoforms
B and C at exerting the specific phenotypic outcome, which
reproduces findings from Siew et al.19. Further, a codon-optimized
version was designed and evaluated in comparison to the wt
version, as previous work has shown that the codon-optimized
version of genes could lead to increased expression20. While we
did not detect differences in expression levels or activity in vitro,
we observed that the codon-optimized version was much more
efficiently expressed than the wt version in the Abcb4−/− mice
following plasmid delivery via HDI. While the reason for this
discrepancy is not clear, there are some indications pointing to a
greater instability of the MDR3-Awt cDNA sequence compared to
MDR3-Aco. First, when cloning MDR3-Awt into AAV plasmids,
frequent mutations and rearrangements were observed, which
were eventually reduced by varying the bacterial strain and
growing them at a lower temperature (30 °C). Second, production
of the AAV-MDR3-Awt vector was very inefficient, resulting in
titres that were routinely two logs lower than equivalent batches
made with the codon-optimized version. These low titres, together
with the low expression observed in the HDI experiments, pointed
to the selection of AAV-MDR3-Aco as the best candidate vector.
In order to further evaluate AAV-MDR3-Aco for efficacy in
correcting the disease, we used a clinically relevant model of
PFIC3 based on Abcb4−/− mice with an FVB genetic background.
Although this animal model presents more severe symptoms in
females than males10, the disease is sufficiently severe in either sex
not to necessitate dietary challenge in contrast to a different
background strain that has been described by others21. We chose
to treat 2-week-old Abcb4−/− mice because young mice represent
a more suitable model for PFIC3 therapy since this disease
manifests in humans early in childhood. In addition, older ani-
mals have a higher level of liver inflammation, a phenomenon
that could potentially reduce AAV-mediated expression22. AAV
transduction was similar in females and males, as observed in
mice analysed 1 week after treatment (Fig. 2 and Supplementary
Fig. 1). However, we observed a clear loss of MDR3 expression in
both males and females when MDR3 staining was compared
between 1 and 12 weeks after treatment (Supplementary Fig. 1),
which was likely due to the still immature livers of these mice at
the time of treatment (2 weeks), resulting in loss of AAV genomes
in part through cell division due to liver growth23. Surprisingly,
MDR3 expression at 12 weeks post-treatment was clearly lower in
females compared to males (Figs. 2 and 5c). It has been observed
by others that AAV-mediated gene transfer in liver is more
efficient in males than in females24,25 regardless of the promoter,
transgene, or mouse strain, and was shown to be related to
androgen-mediated stabilization of viral genomes in males26. In
addition to the well-established increased transduction efficiency
in males, the decreased level of expression in females after
12 weeks could be the result of the female livers being more
diseased, which could lead to a higher loss of MDR3 expression
over time due to liver cell regeneration. However, the loss of
therapeutic effect was observed for only half of the females treated
with a single dose and after 6 weeks. This loss of therapeutic effect
could be the result of insufficient transduction in these animals,
not allowing a minimal threshold of MDR3 expression to be
reached to counteract the effects of the disease. In these condi-
tions, the progression of the disease would therefore predominate,
leading to further liver injury and regeneration, which, possibly in
conjunction with other disease-related factors, could have caused
a gradual loss of vector genomes, the subsequent decrease of
MDR3 expression and drop in bile PC levels even further below
the therapeutic threshold, resulting in bile toxicity, liver damage,
and onset of severe cholestasis.
Evidence supporting the notion of a minimal expression
threshold necessary to revert the disease has been reported
already. De Vree et al. observed that PFIC3 disease could be
reversed in the Abcb4−/− mouse model via transplanting these
mice with primary hepatocytes from healthy WT mice27. With a
repopulation of only 12% Abcb4+/+ hepatocytes, a threshold was
reached and the liver pathology was completely abrogated, with
the correction still present after 1 year. We observed that mice
treated at a lower AAV dose (30% of the high dose) showed no
differences in disease symptoms from saline-treated animals.
Quantification of MDR3-expressing cells for these livers showed
expression to be below 2% of WT mice. Similarly, in the once-
treated high-dose female group, half of the animals also had
expression levels below 2% WT. These animals were those that
lost the therapeutic effect 8 weeks after treatment and that upon
sacrifice had the largest livers and spleens, lowest bile PC
levels, highest degree of liver fibrosis, and greatest evidence of
preneoplasia. We believe that this 2–3% WT level of MDR3-
expressing cells constitutes a threshold above which enough
PC is restored to the bile to prevent the development of
PFIC3 symptoms. Based on our data, the threshold bile PC
concentration above which the disease is prevented appears to be
around 4000 µM (Supplementary Fig. 7). Since neither the exact
amount of vector-mediated protein expression nor the activity of
human MDR3 compared to mouse MDR2 is explicitly known,
this threshold of bile PC concentration may be of more utility
when translating this preclinical research to future studies. The
threshold of 4000 µM of bile PC concentration represents about
12–13% the levels in our WT mice, which is comparable to the
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amount of Abcb4+/+ hepatocyte repopulation reported by de
Vree et al.27. In this way, our approach for PFIC3 could mimic
gene therapies for diseases that involve secreted proteins28, such
as those for haemophilia A and B, α1-antitrypsin deficiency, and
Pompe disease29, in which a small percentage of transduced cells
may be sufficient to reverse the disease.
The Abcb4−/− mouse model allowed us to carry out efficacy
studies in very young mice, which may prove useful when
a b














































































































Fig. 6 Serum biomarker levels for Abcb4−/− mice treated at 5 weeks of age with AAV-MDR3-Aco. The therapeutic effect of AAV treatment is shown in
males (a) and females (b) that were treated with AAV-MDR3-Aco at 1 × 1014 VG/kg one time (1×, red, filled circles; n= 4M/4 F), using as controls saline-
treated (blue, open squares; n= 3M/4 F) and untreated Abcb4+/+ (WT) mice (black, open circles; n= 3M/3 F). Data are presented as mean+ SD. ALP
alkaline phosphatase, ALT alanine transaminase, AST aspartate transaminase, BS bile salts. Source data are provided as a Source Data file.
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translating to the clinic, since children afflicted with PFIC3 will be
a target population for treatment. Any variability in disease
severity among individual animals may be a drawback of the
model, but human PFIC3 patients also constitute a highly het-
erogenous population due to the myriad mutations in the ABCB4
gene that lead to a wide range of phenotypes encompassing
everything from a lack of MDR3 to enzymatic dysfunction to only
impaired activity. It may turn out that achieving a therapeutic
effect via gene therapy could be feasible in only a subset of the
patient population, although we believe most if not all patients in
need of treatment could stand to benefit. Along the same lines,
50% of PFIC3 patients do not respond to the current standard of
care with UDCA, with those that maintain a certain level of
MDR3 activity being the ones that most benefit from this
therapy30,31. If AAV-mediated gene restoration can increase
MDR3 activity even only slightly in patients that do not currently
benefit from UDCA, it may be sufficient to make them UDCA-
therapy responders.
To our surprise, mice that were treated with an already
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Sirius red staining
Spleen weight
Fig. 7 PFIC3 disease parameters in Abcb4−/− mice treated at 5 weeks of age with AAV-MDR3-Aco. At the time of sacrifice, liver (a) and spleen
(b) weight as a percent of body weight, PC concentration in bile (c), liver fibrosis (d), AAV genomes (e), MDR3 transcripts (f), and MDR3 protein
expression (g) were measured for Abcb4−/− mice treated with AAV-MDR3-Aco at 1 × 1014 VG/kg 1× (green triangles; n= 4M/3 F), and saline-treated
controls (open circles; n= 3M/4 F) and untreated WT mice (black diamonds; n= 3M/3 F). Animals were sacrificed 12 weeks after treatment. Statistics
(one-way ANOVA/Tukey’s multiple comparisons test): *, p < 0.05; **, p < 0.01; ***, p < 0.001, ****, p < 0.0001. a–d F values and degrees of freedom
(numerator, denominator): a males: F(2,7)= 44.52, females: F(2,7)= 3.558; b males: F(2,7)= 265.5, females: F(2,7)= 30.81; c males: F(2,7)= 69.93,
females: F(2,7)= 35.8; d males: F(2,6)= 21.02, females: F(2,8)= 39.88. e–g Unpaired t test (t-value and degree of freedom): e males: (t= 3.938, df= 5),
females: (t= 1.737 df= 5); f males: (t= 3.557, df= 5), females: (t= 1.836, df= 5); g males: (t= 12.61, df= 5), females: (t= 1.37, df= 5). Source data are
provided as a Source Data file.
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much the same way to the treatment as the 2-week-old mice. This
bodes well for translation into the clinic where the patient
population will already present symptoms of the disease at time of
diagnosis.
We also report here an improvement in all parameters in mice
treated twice with the AAV vector, which resulted in higher AAV
transduction and MDR3 transgene expression compared to a
single treatment, with no long-term adverse effects. The efficacy
of the second treatment can be explained by immaturity of the
immune system at the time of the first injection, or to the fact that
the second dose was given prior to the peak anti-AAV neu-
tralizing antibody level being reached. In the clinic, several
options exist for developing therapies involving repeated
administrations, including the use of different AAV serotypes for
subsequent injections32,33 and immune modulators to control the
potential immune responses to AAV34.
Two very recent studies published during the revision of this
manuscript have also addressed the possibility of treating PFIC3
by using AAV-mediated gene therapy19,21. In one of these stu-
dies, therapeutic efficacy was only achieved by using a
transposon-mediated integration strategy19, something that could
complicate translation into the clinic due to the potential onco-
genicity of the treatment. In the second study, AAV-based ther-
apy was tested in an Abcb4−/− mouse model with C57BL/6
background that does not develop PFIC3 symptoms unless
challenged with a bile-acid-supplemented diet21. Although this
therapy was successful, the absence of PFIC3 symptoms in these
mice at the time of treatment greatly facilitates the transduction
and maintenance of AAV vectors, a situation that will not be
likely in patients.
In summary, we report here a sustained and significant reversal
of PFIC3 disease biomarkers following treatment using an AAV
vector harbouring a codon-optimized sequence of MDR3 isoform
A in Abcb4−/− mice treated at 2 or 5 weeks of age. In a subset of
the 2-week-old female population, a second AAV injection three
weeks later was required to maintain the therapeutic effect. These
results support the major interest of this approach as a curative
therapy for this debilitating and life-threatening disease in
patients who are faced with limited treatment options.
Methods
Cell lines. HuH-7 (Japanese Collection of Research Bioresources Cell Bank: 0403)
and HEK-293T (ATCC® CRL-3216™) cells were grown in DMEM (Gibco BRL)
supplemented with 10% FBS, 2 mM glutamine, and 100 μg/mL streptomycin and
100 U/mL penicillin.
Cloning and construction of AAV vectors. Synthetic wildtype and codon-
optimized sequences of human ABCB4 cDNA coding for MDR3 isoforms A (NCBI
Reference Sequence: NP_000434.1), B (NP_061337.1), and C (NP_061338.1) were
obtained from GenScript (Nanjing, China) cloned into pUC57 flanked by SalI and
NdeI sites (pU57-MDR3). To generate AAV-MDR3 plasmids, the DNA fragment
coding for each MDR3 isoform variant was extracted by SalI and NdeI digestion
from pUC57-MDR3 and subcloned into a pAAV2 cloning plasmid previously
generated in our laboratory using the same restriction sites, resulting in pAAV-
MDR3-Aco, pAAV-MDR3-Awt, pAAV-MDR3-Bco, pAAV-MDR3-Bwt, pAAV-
MDR3-Cco, and pAAV-MDR3-Cwt plasmids. These plasmids contain wild-type
AAV2 inverted terminal repeats (ITRs) and have the corresponding MDR3 open
reading frame (ORF) downstream of the human A1AT liver-specific promoter35
and a synthetic polyadenylation signal36 at the 3′ end of the ORF.
Production of AAV vectors. To produce AAV viral particles (VPs) with serotype
AAV8, 150-cm2 flasks containing confluent HEK-293T cells were co-transfected
using linear polyethyleneimine 25 kDa (Polysciences, Warrington, PA) with two
different plasmids: pAAV-MDR3-Aco and pDP8.ape (Plasmid Factory, Germany),
which contain adenoviral helper genes plus AAV2 rep and AAV8 cap genes. After
72 h, the supernatant was collected and treated with polyethylene glycol solution
(PEG8000, 8% v/v final concentration) for 48–72 h at 4 °C. Supernatant was cen-
trifuged at 1378×g for 15 min and the pellet was resuspended in lysis buffer
(50 mM Tris-Cl, 150 mM NaCl, 2 mM MgCl2, 0.1% Triton X-100) and kept at
−80 °C. Cells containing AAV VPs were collected and treated with lysis buffer and
frozen at −80 °C. After three cycles of freezing and thawing, VPs obtained from cell
supernatants and lysates were purified by ultracentrifugation at 350,000×g during
2.5 h in a 15–57% iodioxanol gradient37. Finally, the purified virus was con-
centrated using Amicon Ultra Centrifugal Filters-Ultracel 100K (Millipore). AAV-
MDR3 vector titres (VG/mL) were determined by quantitative PCR (qPCR). VGs
were extracted from DNAase-treated VPs using the High Pure Viral Nucleic
Acid Kit (Roche). The primers specific for A1AT promoter were used for
qPCR are listed in Supplementary Table 1. Vector titres ranged from 1 × 1013
to 3 × 1013 VG/mL.
Analysis of MDR3 expression and activity in vitro. HuH-7 cells were transfected
with pAAV-MDR3 plasmids using lipofectamine 2000 (Thermo Fisher). Cells were
fixed at 48–72 h and MDR3 expression was detected by immunofluorescence using
a primary mouse monoclonal antibody specific for MDR3 (Millipore clone P3-II-
26, 1:100). A donkey anti-mouse Alexa-488-conjugated antiserum (Invitrogen ref.
A21202, 1:1000) was used for detection. For activity analysis, after transfection cells
were washed with fresh medium and incubated with DMEM containing 0.1%
bovine serum albumin (BSA) in the presence of 0.5 mM sodium taurocholate
(NaTC). After incubation for 24 h, the content of PC in the medium was deter-
mined using a Phosphatidylcholine Assay Kit (Sigma, MO) according to the
manufacturer’s instructions. Transfection efficiency was checked by using iQ™
SYBR Green (BioRad) in a CFX96 Real-Time Detection System (BioRad) with
primers specific for the A1AT liver promoter that are listed in Supplementary
Table 1.
Animal studies. FVB.Mdr2−/− mice (FVB.129P2-Abcb4tm1Bor) (Abcb4−/−) (JAX
stock #002539)9 as well as FVB.Mdr2+/+ (Abcb4+/+) mice (The Jackson Labora-
tory, Bar Harbor, ME) were bred in our own facilities (Cima Universidad de
Navarra, Pamplona, Spain). Mice were housed with a 12 h light–dark cycle and
received water and food ad libitum using a standard chow diet. In the case of
plasmid-treated animals, mice were injected with 25 μg of pAAV-MDR3-Aco or
pAAV-MDR3-Awt using the hydrodynamic injection-based procedure38 and
sacrificed 24 h later. Treatment with AAV vectors were performed in male and
female mice at 2 and 5 weeks of age by retro-orbital IV injection. For sera analysis,
mice were bled retro-orbitally at the indicated times. Liver, spleen, and gallbladder
samples were collected from euthanized mice for organ size, PC determination,
histological analysis, and nucleic acid extraction. All animal experiments and
procedures were conducted in compliance to ethical regulations for animal testing
and the studies were reviewed and approved by the Universidad de Navarra
Institutional Ethical Committee (protocol numbers: 082c-17 for breeding and 086-
17 for animal studies).
Analysis of serum and bile samples. Serum was separated from whole blood by
centrifuging at 2300×g for 15 min in a microfuge. Serum ALP, ALT, AST, and total
bile salts were quantified using a HITACHI C311 analyzer. For analysis of bile,
mice were fasted for 24 h, sacrificed, and the gallbladder was carefully excised and
placed in a 1.5-mL Eppendorf tube. Then the gallbladder was punctured with a 29G
U100 insulin needle repeatedly to release bile, from which 2 µL were used to
measure PC levels using the Phosphatidylcholine Assay Kit (Sigma) according to
the manufacturer’s instructions.
Nucleic acid extraction and qPCR. Vector genome copies present in liver extracts
were determined by qPCR using iQ™ SYBR® Green (BioRad) in a CFX96 Real-
Time Detection System (BioRad) with primers specific for the A1AT liver pro-
moter. Mouse GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as a
normalizing gene (primers listed in Supplementary Table 1).
To analyse transgene and preneoplasia marker expression, total RNA was
isolated from livers using the Maxwell® 16 LEV simplyRNA Tissue Kit (Promega)
according to manufacturer’s instructions and quantified. Extracted RNA was
reverse transcribed into complementary DNA (cDNA) using M-MLV reverse-
transcriptase (Invitrogen). qPCR was performed using TaqMan primers and probes
specific for codon-optimized-MDR3 (FAM, NFQ-MGB) and mouse GADPH
(VIC, NFQ-MGB) or mouse albumin (FAM, NFQ-MGB) designed by Applied
Biosystems (sequences of which were not provided to the researchers) and run on a
ViiA 7 (ThermoFisher). For neoplasia markers, qPCR was performed with iQ™
SYBR Green (BioRad) in a CFX96 Real-Time Detection System (BioRad) (primers
listed in Supplementary Table 1) using GAPDH as a normalizing gene.
Histological analysis of paraffin embedded sections. Livers were collected from
euthanized mice at the indicated time points. Formalin-fixed paraffin-embedded
liver sections (3 µm thick) were dewaxed and hydrated. Antigen retrieval was
performed using a solution of 20 µg/mL proteinase K for 30 min at 37 °C. For
MDR3 staining, endogenous peroxidase was blocked with 3% H2O2 in deionized
water and liver sections were incubated overnight at 4 °C with anti-MDR3 antibody
diluted 1:2000 (LS-B5729, LS-Bio, Seattle WA) or with anti-phosphorylated histone
H2AX (γH2AX) diluted 1:400 (#9718, Cell Signalling, Danvers, MA). After rinsing
in TBS-Tween, samples were incubated with undiluted goat anti-rabbit EnVision
(K4002, Dako, Glostrup, Denmark) for 30 min and peroxidase activity was revealed
using 3,3′-diaminobenzidine (Dako). Finally, sections were lightly counterstained
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with Harris haematoxylin, dehydrated, and coverslipped. Liver sections were also
stained with haematoxylin and eosin (H&E) for routine histology and with
picrosirius red to analyse liver fibrosis.
Image analysis. Several FIJI V1.46b plugins (ImageJ) were developed by the
Imaging Core Facility (CIMA, Universidad de Navarra) for image analysis. Plugins
contain image-processing operations, like colour segmentation, filtering and par-
ticle counting, which facilitate tissue segmentation from background and allow
determination of the ratio of positive area versus total tissue area. Using FIJI
plugins, collagen, MDR3 or γH2AX present in livers were quantified. The quan-
tification was expressed as the percentage of positive tissue area (collagen), positive
nuclei (γH2AX), or percentage of positive-stained area normalized to MDR2 signal
observed in WT mice (MDR3).
Statistical analysis. Data are presented as mean values ± standard deviation and
were statistically analysed separately for males and females using a one-way
ANOVA test and Tukey’s multiple comparison test or using unpaired t test when
there were only two groups (p < 0.05 was considered significant) with GraphPad
Prism 7.05 software (GraphPad Software Inc., CA, USA).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The source data underlying Figs. 1c, 3a–c, 4a–c, 5a–c, 6a, b, and 7a–g, and
Supplementary Figs. 1, 2, 3a, 4a, b, 5a, 6a, b, 7a, b, 8a, b, and 9a, b are provided as a
Source Data file. The datasets generated during and/or analysed during the current study
are available from the corresponding author on reasonable request.
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